FindTrial
Sign In

Clinical Trial of Shwitrahar lep And Shwitrahar vati on Shwitra with special reference to vitiligo

An open randomised controlled clinical trial of Shwitrahar Lep and Shwitrahar vati on Shwitra with special reference to vitiliogo - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099509
Enrollment
80
Registered
2025-12-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Dr Abhijeet Manmath Morale
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patient aged between 16 to 60 years patient having signs and symptoms of shwitra on mukhapradeshi only patient ready to abide trial procedure to give informed concent

Exclusion criteria

Exclusion criteria: pregnant women and lactating mothers patients having Shwitra on lips and eyelids patients haing skin disorder psoriasis seborrheic dermatitis lichen simplex pityriasis esicular eczema candidacies patients having chronic illness like Diabetes mellitus atopic dermatitis other serious systemic disease

Design outcomes

Primary

MeasureTime frame
efficacy of Shwitrahar lepa use externally in morning and Shwitrahar vati 500mg orally twice in a day on Mukhapradeshi ShwitraTimepoint: 12 weeks or 90 days—

Secondary

MeasureTime frame
efficacy of bauchi tail use externally in morning & shwitrahar vati 500mg twice in day orallyTimepoint: 12 weeks or 90 days;compare the efficacy of shwitrahar lep & bakuchi tailTimepoint: 12 weeks or 90 days—

Countries

India

Contacts

Public ContactAbhijeet Manmath Morale

Yashwant ayurvedic college Post graduate training and research centre,kodoli

suryakiran_wagh@rediffmail.com9822846910

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026